Dianthus Therapeutics 320% Year: What Investors Should Know as Stakes Shift
Dianthus Therapeutics has surged 320% over the past year, even as a large investor reduced its stake. This article di...
This guide highlights dividend ETFs with the lowest expense ratios and explains how expense structures influence long-term performance.
27,554 articlesDianthus Therapeutics has surged 320% over the past year, even as a large investor reduced its stake. This article di...
A half-century-old rule for scaling software teams is breaking as AI fueled capital changes how firms grow. Investors...
A lump-sum windfall sitting in cash while markets churn often misses the gains of staying invested. Experts say a dis...
Investors eye SpaceX's potential IPO as the space economy broadens; public peers already provide exposure across laun...
A Texas primary shock sends markets into a risk-off mode as sen. john cornyn becomes a flashpoint for party fault lin...
A leading analyst questions SpaceX's IPO math and governance, casting doubt on the deal's potential for investors. He...
Florida moves to curb risky AI use, setting the stage for OpenAI’s next legal battle. The actions could alter how inv...
SpaceX priced its IPO terms at $135 per Class A share, issuing 555.6 million shares to raise about $75 billion and va...
Silicon Valley’s long-running belief that technology could change the world is fading as market realities and politic...
NVIDIA CEO Jensen Huang positioned the latest AI stock pullback as a buying opportunity, a stance that reminds invest...
A hotter-than-expected inflation reading paired with robust payroll gains left the newly named Fed chair navigating a...
LISC CEO Michael Pugh warns that housing costs outpace wages are widening the affordability gap. The charity-finance ...